CA3232632A1 - Caix targeting il-12 fusion proteins and methods of use thereof - Google Patents

Caix targeting il-12 fusion proteins and methods of use thereof Download PDF

Info

Publication number
CA3232632A1
CA3232632A1 CA3232632A CA3232632A CA3232632A1 CA 3232632 A1 CA3232632 A1 CA 3232632A1 CA 3232632 A CA3232632 A CA 3232632A CA 3232632 A CA3232632 A CA 3232632A CA 3232632 A1 CA3232632 A1 CA 3232632A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
polypeptide
hil
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3232632A
Other languages
English (en)
French (fr)
Inventor
Jaya BHATNAGAR
Arvind Vittal GOSWAMI
Harish Kumar TRIPURANA
Pradip Nair
Ramakrishnan Melarkode SUBBARAMAN
Shiv Ram KRISHN
Srinivas Reddy Boreddy
Reshmi Nair
Avanish K. VARSHNEY
Seng-Lai TAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bicara Therapeutics Inc
Original Assignee
Bicara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicara Therapeutics Inc filed Critical Bicara Therapeutics Inc
Publication of CA3232632A1 publication Critical patent/CA3232632A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3232632A 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof Pending CA3232632A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245523P 2021-09-17 2021-09-17
US63/245,523 2021-09-17
PCT/US2022/043762 WO2023043978A2 (en) 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3232632A1 true CA3232632A1 (en) 2023-03-23

Family

ID=85603506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3232632A Pending CA3232632A1 (en) 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof

Country Status (11)

Country Link
US (1) US20240392031A1 (https=)
EP (1) EP4402158A4 (https=)
JP (1) JP2024534468A (https=)
KR (1) KR20240161081A (https=)
CN (1) CN118369331A (https=)
AU (1) AU2022345103A1 (https=)
CA (1) CA3232632A1 (https=)
IL (1) IL311442A (https=)
MX (1) MX2024003275A (https=)
WO (1) WO2023043978A2 (https=)
ZA (1) ZA202402034B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
WO2025012105A2 (en) * 2023-07-07 2025-01-16 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Muteins of human interleukin 12
WO2025101133A1 (en) * 2023-11-10 2025-05-15 Agency For Science, Technology And Research Interleukin-12 variants and medical uses thereof
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
WO2025205534A1 (ja) * 2024-03-25 2025-10-02 積水メディカル株式会社 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
IL297186A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Transgenic il-12 and il-23 polypeptides and their uses

Also Published As

Publication number Publication date
MX2024003275A (es) 2024-05-07
EP4402158A4 (en) 2025-07-30
AU2022345103A1 (en) 2024-03-28
WO2023043978A3 (en) 2023-09-28
US20240392031A1 (en) 2024-11-28
CN118369331A (zh) 2024-07-19
ZA202402034B (en) 2025-06-25
KR20240161081A (ko) 2024-11-12
WO2023043978A2 (en) 2023-03-23
JP2024534468A (ja) 2024-09-20
IL311442A (en) 2024-05-01
EP4402158A2 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
CA3232632A1 (en) Caix targeting il-12 fusion proteins and methods of use thereof
EP3218411B1 (en) Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
US20250270313A1 (en) Cldn18.2 antibody and use thereof
EP4101867A1 (en) Anti-cd3 and anti-cd123 bispecific antibody and use thereof
US20230364255A1 (en) Transglutaminase-mediated conjugation
US20230183372A1 (en) Compositions and Methods for Treating Cancer Expressing CD90 and CD326
US20210277139A1 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
EP4495140A1 (en) Claudin18.2 humanized antibody and application thereof
TW202016144A (zh) 包括cd3抗原結合片段之組成物及其用途
US20240228620A1 (en) Multispecific proteins and related methods
WO2022187710A1 (en) Epha2 antibodies
US20240190934A1 (en) Engineered interleukin-10 and fusion proteins thereof
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
HK40114345A (zh) Caix靶向型il-12融合蛋白及其使用方法
US20240043561A1 (en) Humanized antibodies and fragments thereof binding to carbohydrate antigens and uses thereof
US20250197507A1 (en) Cd161 binding proteins and related methods
HK40121523A (zh) 多特异性蛋白及相关方法
EP4725970A1 (en) Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody
CN121758624A (zh) 结合人cd16和/或人cd123的多种抗体及其用途
WO2024141014A1 (zh) Cd74的医药用途
WO2025075858A2 (en) ANTI-IL13Rα2 ANTIBODY COMPOSITIONS AND USES THEREOF
KR20250129696A (ko) Pd-l1을 표적으로 하고 gas6를 중화하는 융합 단백질 및 이의 용도
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
CN121591909A (zh) 抗il-8抗体、抗pd-l1和il-8的多特异性抗体和用途
HK40113281A (zh) Cd74的医药用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250912